Australia's most trusted
source of pharma news
Wednesday, 05 February 2025
Posted 3 February 2025 AM
Johnson & Johnson Innovative Medicine has finally received a PBAC recommendation for its nasal antidepressant Spravato - 1,364 days after it was listed on the ARTG.
Spravato got the tick for treatment resistant depression in adults with Major Depressive Disorder who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat their current moderate-to-severe depressive episode.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.